CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival.
CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival.
复制标题
DOI：
10.1007/s00408-010-9232-9
复制
发表时间：
2010-06
期刊：
影响因子：
5
通讯作者：
Dweik RA
中科院分区：
文献类型：
--
作者：
Heresi GA;Aytekin M;Newman J;Dweik RA
CXC趋化因子配体10（CXCL 10）抑制血管生成并吸引活化的T淋巴细胞。异常血管生成和淋巴细胞浸润参与了肺动脉高压（PAH）的病理生理过程。我们假设血清CXCL 10在特发性PAH中升高，并且与临床结局相关。这是一项队列研究，包括40例特发性PAH患者（年龄= 44 ± 14岁，37例女性）和22例健康对照（年龄= 35 ± 6岁，18例女性）。它发生在克利夫兰诊所的肺血管项目。血清CXCL 10水平通过酶联免疫吸附试验测定。从受试者工作特征曲线（ROC）中获得最佳区分存活和死亡患者的CXCL 10截止值。根据适当的CXCL 10水平，通过Kaplan-Meier方法推导生存期和至临床恶化时间曲线，并通过对数秩检验进行比较。通过考克斯比例风险回归分析检验CXCL 10和其他相关变量的预后价值。与对照组相比，PAH受试者的血清CXCL 10水平升高[PAH的CXCL 10 pg/ml（平均值± SEM）：306 ± 73，对照组：92 ± 10; p < 0.0001]。CXCL 10水平高于111 pg/ml区分幸存者和非幸存者的敏感性为81%，特异性为75%（ROC曲线下面积= 0.74）。自静脉采样之日起平均随访23.5 ± 13.5个月后，较高的CXCL 10水平与生存率改善相关（死亡率风险比= 0.10，95%置信区间= 0.01-0.97; p = 0.01）。肺动脉高压患者血清CXCL 10升高，这与生存期改善相关。
CXC-chemokine ligand 10 (CXCL10) inhibits angiogenesis and attracts activated T lymphocytes. Abnormal angiogenesis and lymphocytic infiltration participate in the pathobiology of pulmonary arterial hypertension (PAH). We hypothesized that serum CXCL10 is elevated in idiopathic PAH and that it is associated with clinical outcomes. This was a cohort study that included 40 idiopathic PAH patients (age = 44 ± 14 years, 37 females) and 22 healthy controls (age = 35 ± 6 years, 18 females). It took place at the Pulmonary Vascular Program at the Cleveland Clinic. Serum CXCL10 levels were measured by an enzyme-linked immunosorbent assay. A cutoff value of CXCL10 for best distinguishing alive and dead patients was obtained from a receiver operating characteristic curve (ROC). Survival and time to clinical worsening curves according to the appropriate CXCL10 level were derived by the Kaplan–Meier method and compared by means of the log-rank test. The prognostic value of CXCL10 and of other variables of interest was tested by Cox proportional hazards regression analysis. Serum CXCL10 levels were elevated in PAH subjects compared to controls [CXCL10 pg/ml (mean ± SEM) for PAH: 306 ± 73, and for controls: 92 ± 10; p < 0.0001]. CXCL10 levels higher than 111 pg/ml discriminated survivors from nonsurvivors with a sensitivity of 81% and a specificity of 75% (area under the ROC curve = 0.74). After a mean follow-up of 23.5 ± 13.5 months since the day of venous sampling, higher CXCL10 levels were associated with improved survival (hazard ratio for mortality = 0.10, 95% confidence interval = 0.01–0.97; p = 0.01). Serum CXCL10 is elevated in PAH and this is associated with improved survival.
登录
查看更多内容
DOI：
10.1084/jem.184.3.963
发表时间：
1996-09-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Loetscher M;Gerber B;Loetscher P;Jones SA;Piali L;Clark-Lewis I;Baggiolini M;Moser B
通讯作者：
Moser B
DOI：
10.1164/rccm.200709-1369pp
发表时间：
2008-09-15
影响因子：
24.7
作者：
Rai, Pradeep R.;Cool, Carlyne D.;Voelkel, Norbert F.
通讯作者：
Voelkel, Norbert F.
DOI：
10.1084/jem.182.1.155
发表时间：
1995-07-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Angiolillo AL;Sgadari C;Taub DD;Liao F;Farber JM;Maheshwari S;Kleinman HK;Reaman GH;Tosato G
通讯作者：
Tosato G
DOI：
10.1164/rccm.2012112
发表时间：
2002-02-15
影响因子：
24.7
作者：
Dorfmüller, P;Zarka, V;Humbert, M
通讯作者：
Humbert, M
DOI：
10.1164/rccm.2107139
发表时间：
2002-05-15
影响因子：
24.7
作者：
Saetta, M;Mariani, M;Fabbri, LM
通讯作者：
Fabbri, LM